Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 5Thoracic 4Breast 3Head & Neck 2Lymphoid 1Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 550Head and Neck Neoplasms 490Carcinoma, Non-Small-Cell Lung 338Melanoma 217Colorectal Neoplasms 206Ovarian Neoplasms 174Neoplasms 171Breast Neoplasms 168Stomach Neoplasms 141Carcinoma, Renal Cell 133Uterine Cervical Neoplasms 129Neoplasm Metastasis 129Triple Negative Breast Neoplasms 125Lung Neoplasms 118Pancreatic Neoplasms 117Esophageal Neoplasms 107Thyroid Neoplasms 95Endometrial Neoplasms 93Urinary Bladder Neoplasms 92Prostatic Neoplasms 88Sarcoma 81Carcinoma, Squamous Cell 81Carcinoma, Transitional Cell 75Small Cell Lung Carcinoma 74Carcinoma, Hepatocellular 65Recurrence 53Nasopharyngeal Carcinoma 52Carcinoma 47Colonic Neoplasms 46Cholangiocarcinoma 43

Interventions

Rogaratinib 1Drug Combinations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Acrocephalosyndactylia × Head & Neck × Clear all
NCT03144661 2025-10-21

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Incyte Corporation

Phase 1 Terminated
25 enrolled
GastrointestinalGynecologicHead & Neck

Acrocephalosyndactylia, Esophageal Neoplasms, Carcinoma, Hepatocellular, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma

NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Bayer

Phase 2 Completed
1 enrolled
BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡